RASSF10 suppresses colorectal cancer growth by activating P53 signaling and sensitizes colorectal cancer cell to docetaxel

Oncotarget

Volumn 6, Issue 6, 2015, Pages 4202-4213

  Guo, Jing ^a   Yang, Yage ^a,b   Yang, Yunsheng ^a   Linghu, Enqiang ^a   Zhan, Qimin ^c   Brock, Malcolm V ^d   Herman, James G ^d   Zhang, Bingyong ^e   Guo, Mingzhou ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^c CANCER HOSPITAL   (China)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Colorectal cancer; DNA methylation; Epigenetics; P53 signaling; RASSF10

Indexed keywords

CASPASE 3; DOCETAXEL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; PROTEIN RASSF10; SURVIVIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; RASSF10 PROTEIN, HUMAN; TAXOID; TP53 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; COLORECTAL CANCER; CONCENTRATION RESPONSE; DNA DAMAGE; DNA METHYLATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; IC50; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MITOSIS; MOUSE; NONHUMAN; ONCOGENE; PATHOGENESIS; PROMOTER REGION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RASSF10 GENE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; GENETIC EPIGENESIS; GENETIC TRANSFECTION; GENETICS; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GENES, P53; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; TAXOIDS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924266603     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2866     Document Type: Article

References (35)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer. 2010; 127:2893-2917.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61:759-767.
3. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer Genome Landscapes. Science. 2013; 339:1546-1558.
4. Guo M, Ren J, Brock MV, Herman JG, Carraway HE. Promoter methylation of HIN-1 in the progression to esophageal squamous cancer. Epigenetics: official journal of the DNA Methylation Society. 2008; 3:336-341.
5. Guo M, Ren J, House MG, Qi Y, Brock MV, Herman JG. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12:4515-4522.
6. Jia Y, Guo M. Epigenetic changes in colorectal cancer. Chinese journal of cancer. 2013; 32:21-30.
7. Heyn H, Mendez-Gonzalez J, Esteller M. Epigenetic profiling joins personalized cancer medicine. Expert review of molecular diagnostics. 2013; 13:473-479.
8. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, Rudek MA, Belinsky SA, Herman JG, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer discovery. 2011; 1:598-607.
9. Djos A, Martinsson T, Kogner P, Caren H. The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma. Molecular cancer. 2012; 11:40.
10. Sherwood V, Manbodh R, Sheppard C, Chalmers AD. RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis. Molecular biology of the cell. 2008; 19:1772-1782.
11. Richter AM, Walesch SK, Wurl P, Taubert H, Dammann RH. The tumor suppressor RASSF10 is upregulated upon contact inhibition and frequently epigenetically silenced in cancer. Oncogenesis. 2012; 1:e18.
12. Sherwood V, Recino A, Jeffries A, Ward A, Chalmers AD. The N-terminal RASSF family: a new group of Ras-association-domain-containing proteins, with emerging links to cancer formation. The Biochemical journal. 2010; 425:303-311.
13. Underhill-Day N, Hill V, Latif F. N-terminal RASSF family: RASSF7-RASSF10. Epigenetics: official journal of the DNA Methylation Society. 2011; 6:284-292.
14. Dansranjavin T, Wagenlehner F, Gattenloehner S, Steger K, Weidner W, Dammann R, Schagdarsurengin U. Epigenetic down regulation of RASSF10 and its possible clinical implication in prostate carcinoma. The Prostate. 2012; 72:1550-1558.
15. Helmbold P, Richter AM, Walesch S, Skorokhod A, Marsch W, Enk A, Dammann RH. RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi. The Journal of investigative dermatology. 2012; 132:687-694.
16. Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R, Griffiths M, Chalmers AD, Maher ER, Latif F. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Molecular cancer. 2009; 8:42.
17. Hill VK, Underhill-Day N, Krex D, Robel K, Sangan CB, Summersgill HR, Morris M, Gentle D, Chalmers AD, Maher ER, Latif F. Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene. 2011; 30:978-989.
18. Lu D, Ma J, Zhan Q, Li Y, Qin J, Guo M. Epigenetic silencing of RASSF10 promotes tumor growth in esophageal squamous cell carcinoma. Discovery medicine. 2014; 17:169-178.
19. Schagdarsurengin U, Richter AM, Wohler C, Dammann RH. Frequent epigenetic inactivation of RASSF10 in thyroid cancer. Epigenetics: official journal of the DNA Methylation Society. 2009; 4:571-576.
20. Wei Z, Chen X, Chen J, Wang W, Xu X, Cai Q. RASSF10 is epigenetically silenced and functions as a tumor suppressor in gastric cancer. Biochemical and biophysical research communications. 2013; 432:632-637.
21. Iwasa H, Kudo T, Maimaiti S, Ikeda M, Maruyama J, Nakagawa K, Hata Y. The RASSF6 tumor suppressor protein regulates apoptosis and the cell cycle via MDM2 protein and p53 protein. The Journal of biological chemistry. 2013; 288:30320-30329.
22. Kudo T, Ikeda M, Nishikawa M, Yang Z, Ohno K, Nakagawa K, Hata Y. The RASSF3 candidate tumor suppressor induces apoptosis and G1-S cell-cycle arrest via p53. Cancer research. 2012; 72:2901-2911.
23. Lee D, Park SJ, Sung KS, Park J, Lee SB, Park SY, Lee HJ, Ahn JW, Choi SJ, Lee SG, Kim SH, Kim DH, Kim J, Kim Y, Choi CY. Mdm2 associates with Ras effector NORE1 to induce the degradation of oncoprotein HIPK1. EMBO reports. 2012; 13:163-169.
24. Song MS, Song SJ, Kim SY, Oh HJ, Lim DS. The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex. The EMBO journal. 2008; 27:1863-1874.
25. Fahraeus R, Olivares-Illana V. MDM2's social network. Oncogene. 2014; 33:4365-4376.
26. Liu M, Li C, Pazgier M, Mao Y, Lv Y, Gu B, Wei G, Yuan W, Zhan C, Lu WY, Lu W. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:14321-14326.
27. Nag S, Qin J, Srivenugopal KS, Wang M, Zhang R. The MDM2-p53 pathway revisited. Journal of biomedical research. 2013; 27:254-271.
28. Pei D, Zhang Y, Zheng J. Regulation of p5: a collaboration between Mdm2 and Mdmx. Oncotarget. 2012; 3:228-235.
29. Scrace SF, O'Neill E. RASSF Signalling and DNA Damage: Monitoring the Integrity of the Genome?. Molecular biology international. 2012; 2012:141732.
30. Yan W, Wu K, Herman JG, Brock MV, Fuks F, Yang L, Zhu H, Li Y, Yang Y, Guo M. Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer. Epigenetics. 2013; 8:1373-1383.
31. Jia Y, Yang Y, Brock MV, Zhan Q, Herman JG, Guo M. Epigenetic regulation of DACT2, a key component of the Wnt signalling pathway in human lung cancer. J Pathol. 2013; 230:194-204.
32. Jia Y, Yang Y, Liu S, Herman JG, Lu F, Guo M. SOX17 antagonizes WNT/beta-catenin signaling pathway in hepatocellular carcinoma. Epigenetics: official journal of the DNA Methylation Society. 2010; 5:743-749.
33. McGinnis W, Krumlauf R. Homeobox genes and axial patterning. Cell. 1992; 68:283-302.
34. Cregger M, Berger AJ, Rimm DL. Immunohistochemistry and quantitative analysis of protein expression. Archives of pathology & laboratory medicine. 2006; 130:1026-1030.
35. Koo CL, Kok LF, Lee MY, Wu TS, Cheng YW, Hsu JD, Ruan A, Chao KC, Han CP. Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. Journal of translational medicine. 2009; 7:25.